RU-2026105910-A - CRYSTALLINE FORM H1 OF 5-((3R,5S)-3-AMINO-5-(TRIFLUOROMETHYL)PIPERIDINE-1-YL)QUINOLINE-8-CARBONITRILE HEMIHYDRATE

Inventors

• ЧАМОРРО ОРУЭ Аналия Иванна
• Хаферкамп Свен
• БОК Доминик Анна
• Меллор Анна

Assignees

• МЕРК ПАТЕНТ ГМБХ

Dates

Publication Date

20260507

Application Date

20240808

Priority Date

20230809

Claims (11)

1. 1. A crystalline polymorph of 5-((3R,5S)-3-amino-5-(trifluoromethyl)piperidin-1-yl)quinoline-8-carbonitrile characterized by one or more peaks in a powder X-ray diffraction pattern (XRD), wherein said peaks, expressed in degrees 2θ±0.2°, include 7.2, 9.7, 13.4, 14.3, 17.0, 17.8, 19.9, 20.6, 21.5, 21.9, 22.2, 22.6, 23.0, 23.5, 24.1, 25.1, 25.5, 25.8, 26.4 and 26.9.
2. 2. The crystalline polymorph of claim 1, characterized by two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, sixteen or more, seventeen or more, eighteen or more, nineteen or more, or each of the following PDP peaks, expressed in degrees 2θ±0.2°, 7.2, 9.7, 13.4, 14.3, 17.0, 17.8, 19.9, 20.6, 21.5, 21.9, 22.2, 22.6, 23.0, 23.5, 24.1, 25.1, 25.5, 25.8, 26.4 and 26.9.
3. 3. The crystalline polymorph according to claim 1, characterized by PRD peaks expressed in degrees 2θ±0.2°, including a peak at 13.4.
4. 4. The crystalline polymorph according to claim 1, characterized by PRD peaks expressed in degrees 2θ±0.2°, including peaks at 9.7 and 13.4.
5. 5. The crystalline polymorph according to claim 1, characterized by PRD peaks expressed in degrees 2θ±0.2°, including peaks at 7.2, 9.7 and 13.4.
6. 6. The crystalline polymorph of claim 1, characterized by PRD peaks expressed in degrees 2θ±0.2°, including peaks at 7.2, 9.7, 13.4, and 22.2.
7. 7. The crystalline polymorph of claim 1, characterized by PRD peaks expressed in degrees 2θ±0.2°, including peaks at 7.2, 9.7, 13.4, 21.5 and 22.2.
8. 8. Crystalline polymorph of 5-((3R,5S)-3-amino-5-(trifluoromethyl)piperidin-1-yl)quinoline-8-carbonitrile, characterized by orthorhombic space group P2 1 2 1 2 1 with lattice parameters α=1.07499±0.01 nm (10.7499±0.1 Å), and b=1.64119±0.01 nm (16.4119±0.1 Å), c=1.75927±0.01 nm (17.5927±0.1 Å) and α=γ=β=90°.
9. 9. A pharmaceutical composition comprising a crystalline polymorph according to any one of claims 1-8 and one or more pharmaceutically acceptable carriers.
10. 10. A pharmaceutical composition for use in a method for treating or preventing an autoimmune disease associated with TLR7/8, said composition comprising a crystalline polymorph according to any one of claims 18 and one or more pharmaceutically acceptable carriers.
11. 11. A pharmaceutical composition for use in the method of claim 10, wherein the TLR7/8-associated autoimmune disease is selected from the group consisting of rheumatoid arthritis, autoimmune pancreatitis, lupus, systemic lupus erythematosus, cutaneous lupus erythematosus, diabetes mellitus type 1, multiple sclerosis, antiphospholipid syndrome, sclerosing cholangitis, systemic-onset arthritis, irritable bowel disease, scleroderma, Sjogren's disease, vitiligo, myositis, dermatomyositis, polymyositis, pemphigus vulgaris, pemphigus foliaceus, inflammatory bowel disease, Crohn's disease, ulcerative colitis, autoimmune hepatitis, hypopituitarism, graft-versus-host disease, autoimmune diseases of the skin, uveitis, pernicious anemia, and hypoparathyroidism.